Metastatic colorectal cancer.

Area of Science:

• Oncology
• Medical Research

Background:

• Colorectal cancer (CRC) frequently metastasizes, with limited long-term survival for many patients.
• 5-fluorouracil (5-FU) has been the standard treatment for decades, with limited efficacy improvements through various schedules.
• Newer agents and local therapies are expanding treatment options beyond 5-FU.

Purpose of the Study:

• To review the evolution of colorectal cancer treatment.
• To highlight novel chemotherapeutic agents and targeted therapies.
• To discuss emerging local treatment modalities for metastatic disease.

Main Methods:

• Review of existing literature on colorectal cancer pharmacotherapy and interventional oncology.
• Analysis of clinical trial data for new drug agents.
• Evaluation of emerging local treatment strategies for liver metastases.

Main Results:

• Irinotecan demonstrated improved survival and quality of life in second-line settings and front-line combinations.
• Capecitabine offers an oral alternative for front-line treatment.
• Oxaliplatin shows activity and is approved in Europe.
• Numerous novel agents (EGFR inhibitors, angiogenesis inhibitors, vaccines) are in clinical trials.
• Local therapies (cryosurgery, ablation, HAI) are emerging for liver-confined disease.

Conclusions:

• Significant progress has been made in colorectal cancer treatment beyond 5-FU.
• Combination therapies and novel agents are improving outcomes for metastatic CRC.
• Local therapies provide additional options for selected patients with liver metastases.